NASDAQ · Biotechnology · USD
Neuphoria Therapeutics Inc. (NEUP) Stock Analysis
Neuphoria Therapeutics Inc. (NEUP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
NEUP Key Statistics
As of Oct 21, 2026Trading
- Open
- $3.49
- Previous Close
- $3.39
- Day's Range
- 3.47–3.54
- 52-Week Range
- 3.19–8.44
- Volume
- 8.80K
Valuation
- Market Cap
- $18.83M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 16.04
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −3.06
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$15.49M
- Shares Outstanding
- 5.41M
- 1-Year Return
- −28.25%
Dividend and dates
- Avg Volume
- 160.90K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, NEUP closed at $3.48, −28.25% over 1 year.
Neuphoria Therapeutics Inc. (NEUP) has a market capitalization of $18.83M.
In fiscal 2024, NEUP reported revenue of $0.00.
NEUP Stock Return by Calendar Year
Neuphoria Therapeutics Inc. (NEUP) return since Dec 2021: what $10,000 became
- 1 year
- $10,000 $7,175
- −28.25%
- 3 years
- $10,000 $761
- −92.39%
- Since Dec 2021
- $10,000 $197
- −98.03%
If you had invested $10,000 in Neuphoria Therapeutics Inc. (NEUP) at the close on December 16, 2021, the earliest close on record here, it would have been worth $197 at the close on October 21, 2026: −98.03% in total, −55.54% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −10.31% |
| 2025 | +13.12% |
| 2024 | −80.69% |
| 2023 | −68.17% |
| 2022 | −62.95% |
| 2021 (partial year) | −14.80% |
As of October 21, 2026.
NEUP Revenue and Earnings by Fiscal Year
FY ends June| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2024 | $0.00 | −$15.49M | — |
| 2023 | $0.00 | −$21.38M | — |
| 2022 | $181.36K | −$14.97M | −8,253.6% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2024 | $0.00 | — | −$17.80M | −$15.49M | — |
| 2023 | $0.00 | — | −$21.56M | −$21.38M | — |
| 2022 | $181.36K | — | −$14.68M | −$14.97M | −8,253.6% |
Annual figures as reported, in the company's reporting currency. As of June 30, 2024.
NEUP Valuation vs Biotechnology Median
Median of 608 stocks| Metric | NEUP | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 16.04 | 13.30 | 21% above |
Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B